← All Optimizerx CORP filings

Optimizerx CORP 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
OPRX
Optimizerx CORP
10-Q: OptimizeRx Returns to Profitability Amid Strong Revenue Growth
OptimizeRx Corporation reported a significant financial turnaround, achieving net income for the quarter and nine-month period ended September 30, 2025, driven by robust revenue growth and improved margins.
NASDAQ
OPRX
Optimizerx CORP
10-Q: OptimizeRx Returns to Profitability in Q2 2025
OptimizeRx Corporation reported a significant financial turnaround in Q2 2025, achieving net income and strong revenue growth driven by DTC and DAAP sales.
NASDAQ
OPRX
Optimizerx CORP
10-Q: OptimizeRx Reports Q1 2025 Results: Revenue Up 11% Driven by DTC and DAAP Growth
OptimizeRx's Q1 2025 revenue increased by 11% year-over-year, driven by growth in DTC and DAAP related sales, while net loss decreased significantly.
NASDAQ
OPRX
Optimizerx CORP
10-Q: OptimizeRx Reports 30% Revenue Increase in Q3 2024, Despite Net Loss
OptimizeRx Corporation saw a 30% increase in revenue in the third quarter of 2024 compared to the same period last year, driven by the acquisition of Medicx Health and growth in DAAP related sales, but still reported a net loss.
NASDAQ
OPRX
Optimizerx CORP
10-Q: OptimizeRx Reports Strong Revenue Growth in Second Quarter 2024, Driven by DAAP and Medicx Health Acquisition
OptimizeRx Corporation saw a significant increase in revenue for the second quarter of 2024, primarily due to the acquisition of Medicx Health and growth in its DAAP program.
NASDAQ
OPRX
Optimizerx CORP
10-Q: OptimizeRx Reports 51% Revenue Increase in Q1 2024 Driven by Medicx Health Acquisition and DAAP Growth
OptimizeRx Corporation saw a 51% increase in net revenue in the first quarter of 2024, primarily due to the acquisition of Medicx Health and growth in its DAAP solutions.